A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin

NCT03970798 | Completed Phase 1

• 1 other identifier: 6356-005
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.

Conditions

Parkinson's Disease

Outcome Measures

Primary Outcomes (1)

• Geometric mean ratio of the major pharmacokinetic parameter (AUC0-t) of the index substrates in combination with or without KW-6356

  Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

Secondary Outcomes (9)

• Geometric mean ratio of the major pharmacokinetic parameters (Cmax) of the index substrates in combination with or without KW-6356

  Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

• Geometric mean ratio of the major pharmacokinetic parameters (AUC0-∞) of the index substrates in combination with or without KW-6356

  Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

• Pharmacokinetic parameters (tmax) of the index substrates

  Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

• Pharmacokinetic parameters (CL/F) of the index substrates

  Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

• Pharmacokinetic parameters (Vz/F) of the index substrates

  Starting around 2 hours before intake of the index substrates and continued until 24 hours after the last dose of KW-6356

Study Arms (1)

KW-6356/Healthy Japanese adult male subjects

EXPERIMENTAL

Period 1: intake of the index substrates at Day 1 (Cohort 1: midazolam, Cohort 2: caffeine + rosuvastatin) followed by Period 2: intake of KW-6356 at Day 4-13, intake of the index substrates at Day 11

Drug: Midazolam; Drug: Caffeine; Drug: Rosuvastatin; Drug: KW-6356

Interventions

Midazolam DRUG

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

KW-6356/Healthy Japanese adult male subjects

Caffeine DRUG

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

KW-6356/Healthy Japanese adult male subjects

Rosuvastatin DRUG

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

KW-6356/Healthy Japanese adult male subjects

KW-6356 DRUG

In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.

KW-6356/Healthy Japanese adult male subjects

Eligibility Criteria

• Age: 20 Years - 44 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Individuals having issued written consent to this study at their own discretion
• Japanese males aged 20 to 44 years at the time of informed consent
• Body mass index (BMI) of 18.5 to \<25.0 at screening
• Resting pulse rate of 40 to 100 bpm, systolic blood pressure of 90 to 139 mmHg, and diastolic blood pressure of 40 to 89 mmHg when measured in the supine position at screening

You may not qualify if:

• Individuals with any current disease requiring treatment
• Individuals having drug allergy or its history
• Individuals having psychiatric disease or its history
• Positive results for any of the following infection-related items examined at screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin (PRP) test, Treponema pallidum (TP) antibody.
• Individuals with clinically significant abnormality detected on 12-lead electrocardiogram (ECG) recorded prior to the first dose of index substrate.
• Individuals categorized as patients listed in the warnings or contraindications section of the package insert of any of the relevant index substrates (see separate protocol annex 6-8)
• Individuals having used any drug (including over-the-counter \[OTC\] drugs, topical agents, vitamin preparations, health supplements, and Chinese herbal medicines) within 2 weeks prior to the first dose of index substrate.
• Individuals having consumed grapefruit (including any food or beverage containing grapefruit) or any food or beverage containing St John's wort within 1 week prior to the first dose of index substrate.
• Individuals having smoked or used smoking cessation agents (including chewing or eating of nicotine-containing products and application of nicotine patches) within 4 weeks prior to the first dose of index substrate.
• Individuals having received inpatient treatment or surgery within 12 weeks prior to the first dose of index substrate.
• Individuals having participated in a clinical study of a pharmaceutical product or a medical device or any equivalent study and used the investigational product or the unapproved medical device within 16 weeks prior to the first dose of index substrate.
• Individuals having undergone collection of ≥400 mL of blood within 12 weeks prior to the first dose of index substrate or ≥200 mL of blood within 4 weeks prior to the first dose of index substrate (for blood donation or clinical trial, etc.) or pheresis donation (plateletpheresis or plasmapheresis donation) within 2 weeks prior to the first dose of index substrate.
• Individuals having issued no consent to adoption of any appropriate contraceptive method during a period from day of admission to 12 weeks after the final dose of the study drug. The appropriate contraceptive method is defined as sexual abstinence or use of 2 of the following contraceptive devices: condom, oral contraceptives, intrauterine device, and pessary.
• Individuals having received KW-6356 before.
• Other individuals unsuitable for participating in the study in the opinion of the investigator or subinvestigator.

Sponsors & Collaborators

• Kyowa Kirin Co., Ltd.: lead

Study Sites (1)

Fukuoka Mirai Hospital Clinical Research Center

Fukuoka, Japan

Location

MeSH Terms

Conditions

Parkinson Disease

Interventions

Midazolam; Caffeine; Rosuvastatin Calcium

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Benzodiazepines; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Xanthines; Alkaloids; Purinones; Purines; Sulfonamides; Amides; Organic Chemicals; Fluorobenzenes; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Hydrocarbons; Sulfones; Sulfur Compounds; Pyrimidines; Heterocyclic Compounds, 1-Ring

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 23, 2019
• First Posted: June 3, 2019
• Study Start: May 22, 2019
• Primary Completion: July 31, 2019
• Study Completion: July 31, 2019
• Last Updated: November 29, 2019

Record last verified: 2019-11

Locations

JP (1)